3 completed, 2 recruiting, 1 active not recruiting, 1 unknown. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Recruiting 2, Active not recruiting 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow T-cell Prolymphocytic Leukemia: new trials by email Literature Review of T-cell Prolymphocytic Leukemia trials Research Report on T-cell Prolymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia Ruxolitinib, Cladribine, Venetoclax - T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 36 | 2026-04-28 | 2026-08-12 |
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Itacitinib - Leukemia, Acute, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 32 | 2023-07-06 | 2026-10-07 |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma Ruxolitinib, Duvelisib - T-cell Lymphomas, NK-Cell Lymphomas | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 70 | 2021-08-12 | 2026-09-09 |
| Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia Alemtuzumab, Itacitinib - Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 15 | 2020-01-15 | 2024-10-10 |
| Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) IL-15 plus, alemtuzumab - T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL) | Phase 1 | Completed | National Cancer Institute (NCI) | 11 | 2017-01-19 | 2022-04-29 |
| CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma anti-CD7 CAR-pNK cells - Acute Myeloid Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-03-01 | 2016-12-06 |
| Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine - Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 76 | 1999-09-01 | 2020-01-29 |
Leukemia, Prolymphocytic, T-Cell (7) · Leukemia, Large Granular Lymphocytic (2) · Lymphoma, T-Cell (2) · Enteropathy-Associated T-Cell Lymphoma (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Plasma Cell (1) · Leukemia, Prolymphocytic (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Non-Hodgkin (1)
Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Leukemia, Lymphoid (7) · Leukemia, T-Cell (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Leukemia (6) · Leukemia, Prolymphocytic (6) · Lymphoma (4) · Disease Attributes (3) · Lymphoma, Non-Hodgkin (3)
Alemtuzumab (2) · itacitinib (2) · ruxolitinib (2) · Carmustine (1) · Cladribine (1) · Cyclophosphamide (1) · Cyclosporine (1) · Cyclosporins (1) · Cytarabine (1) · Etoposide (1) · INCB039110 (1) · Interleukin-15 (1) · Melphalan (1) · Mycophenolic Acid (1) · Peripheral Blood Stem Cell Transplantation (1)
M.D. Anderson Cancer Center (2) · Fred Hutchinson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (6) · China (1) · Germany (1)
Alison Moskowitz, MD (1) · David Maloney (1) · Ivana Gojo, MD (1) · Kevin Conlon, M.D. (1) · Lin Yang, Ph.D. (1) · Tapan Kadia, MD (1) · Tapan M Kadia (1)
PMID 28054442, PMID 32499241, PMID 32508818, PMID 33883258, PMID 35475910, PMID 41536780
P30CA015704 (1)